Albert Agro

Dr. Albert Agro joined KALGENE INC on a consultancy basis as acting Chief Medical Officer in August 2021. Prior to him joining the company, Dr. Agro was President and Chief Executive Officer of Sublimity Therapeutics Inc. a clinical-stage biopharmaceutical company headquartered in Ireland, from May 2018 to June 2021. From 2012 till its sale to Sunovion in 2016, Dr. Agro served as the Chief Medical Officer of Cynapsus Therapeutics Inc., a clinical-stage pharmaceutical company focusing on the treartment or Off episodes in patients with Parkinson’s disease. In 2010, Dr. Agro co-Founded GRi Bio, a clinical-stage biotechnology company in La Jolla CA focused on various indications including Multiple Sclerosis. Dr. Agro has held executive clinical positions with TransTech Pharma (now known as vTv Therapeutics), Bayer Inc, Boehringer Ingelheim and Ironshore Pharmaceuticals.

Dr. Agro completed his Doctoral training in Neuroimmunology from the Department of Medicine at McMaster University where he remains an Assistant Professor in the Department of Pathology and Molecular Medicine.